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Abstract
Phenylketonuria (PKU) is caused by hepatic phenylalanine hydroxylase (PAH) deficiency and is associated with
systemic accumulation of phenylalanine (Phe). Previously we demonstrated correction of murine PKU after
intravenous injection of a recombinant type 2 adeno-associated viral vector pseudotyped with type 8 capsid
(rAAV2=8), which successfully directed hepatic transduction and Pah gene expression. Here, we report that liver
PAH activity and phenylalanine clearance were also restored in PAH-deficient mice after simple intramuscular
injection of either AAV2 pseudotype 1 (rAAV2=1) or rAAV2=8 vectors. Serotype 2 AAV vector (rAAV2=2) was
also investigated, but long-term phenylalanine clearance has been observed only for pseudotypes 1 and 8.
Therapeutic correction was shown in both male and female mice, albeit more effectively in males, in which
correction lasted for the entire period of the experiment (>1 year). Although phenylalanine levels began to rise in
female mice at about 8–10 months after rAAV2=8 injection they remained only mildly hyperphenylalaninemic
thereafter and subsequent supplementation with synthetic tetrahydrobiopterin resulted in a transient decrease in
blood phenylalanine. Alternatively, subsequent administration of a second vector with a different AAV pseu-
dotype to avoid immunity against the previously administrated vector was also successful for long-term
treatment of female PKU mice. Overall, this relatively less invasive gene transfer approach completes our
previous studies and allows comparison of complementary strategies in the development of efficient PKU gene
therapy protocols.
Introduction
Phenylketonuria (PKU) is an autosomal recessive geneticdisorder with an average incidence of roughly 1 case in
10,000 Caucasian live births (OMIM 261600). It is caused
primarily by deficiency of the hepatic enzyme phenylalanine
hydroxylase (PAH; EC 1.14.16.1), responsible for converting
phenylalanine to tyrosine, using molecular oxygen and tet-
rahydrobiopterin (BH4) as a necessary cofactor for its catalytic
activity (Scriver and Kaufman, 2001). This conversion is the
rate-limiting step in phenylalanine (Phe) catabolism in the
liver. PAH deficiency due to mutations in the gene that en-
codes PAH leads to hyperphenylalaninemia (HPA), a dra-
matic increase in blood Phe concentration from <0.12 to
>1.2mM (the equivalent of<2 to>20mg=dl). The inability to
degrade Phe present in dietary protein leads to the excretion
of urinary phenylalanine, phenylpyruvate, and phenylace-
tate. Mild forms of PKU accumulate Phe in the blood at levels
of 0.6 to 1.2mM. High levels of accumulated Phe in patients
with PKU are toxic to the human body if left untreated,
and are associated with an abnormal phenotype presenting
with growth failure, microcephaly, seizures, and mental re-
tardation (Donlon et al., 2008). HPA can also be caused by
the absence of the BH4 cofactor due to deficiency of cofactor
biosynthesis and regeneration, which leads to a diverse group
of neurometabolic diseases (Blau et al., 2001; Tho¨ny and Blau,
2006). The biochemistry and genetics of PKU are well char-
acterized, with more than 500 disease-causing mutations
identified in the human PAH gene spread over the entire 13
exon-containing gene (see also the Phenylalanine Hydro-
xylase Locus Knowledgebase [PAHdb], www.pahdb.mc-
gill.ca) (Scriver et al., 2003). Moreover, PKU has been detected
in most Western countries for many decades by newborn
screening programs (Guthrie, 1996).
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HPA during pregnancy can produce PKU-like symptoms
in genetically unaffected offspring, termed maternal PKU
syndrome, which is associated with severe birth defects such
as microcephaly, congenital heart disease, and low birth
weight (Levy and Ghavami, 1996; Guttler et al., 2003). The
current established treatment for PKU consists of life-long
dietary Phe restriction, which is challenging in practice as it
is demanding in schedule, unpleasant in taste, carries risk for
nutritional deficiencies, and is a substantial psychosocial
burden, associated with reduction in quality of life (Harding,
2000; National Institutes of Health Consensus Development
Panel, 2001). Furthermore, it was reported that decline in
intellectual function (Koch et al., 1984), behavioral perfor-
mance (Koch et al., 2002), and severe emotional dysfunction,
including attention deficit disorder (Antshel and Waisbren,
2003), depression, and anxiety (Waisbren and Levy, 1991),
are often observed in noncompliant patients with PKU.
Because of these shortcomings, the focus of PKU research
has shifted since the beginning of the twenty-first century to
the improvement of current therapy and development of
alternative options (Sarkissian et al., 2009). With the prog-
ress in gene delivery, particularly with the advent of adeno-
associated virus (AAV)-based vectors (Wu et al., 2006; Buning
et al., 2008; Schultz and Chamberlain, 2008; Zincarelli et al.,
2008), gene therapy has emerged as an attractive alterna-
tive to meet the particularly challenging issue of long-term
treatment in PKU. Successful correction of murine HPA using
recombinant type 2 AAV vectors pseudotyped with serotype
2 or 5 capsid (rAAV2=2 or rAAV2=5) has been achieved in
several laboratories (Laipis et al., 2004; Mochizuki et al., 2004;
Oh et al., 2004). However, in these AAV experiments, ex-
tremely high doses of viral vectors (1013 to 1014 vector ge-
nomes per mouse) were necessary for efficient reduction
in blood Phe. Moreover, the therapy was less effective in
female mice. In one published study, efficacy was observed
to last 40 weeks in male mice but only 10 weeks in females
(Mochizuki et al., 2004). Gender-dependent differences in
liver transduction with AAV vectors have been reported in
many other studies (Davidoff et al., 2003; Grimm et al., 2003;
Berraondo et al., 2006; Ogura et al., 2006; Voutetakis et al.,
2007; Ho et al., 2008) and could complicate human clinical
trials, with important implications for the prevention of
maternal PKU. Furthermore, other factors, such as stability
of the PAH protein (Harding et al., 2006a), subphysiological
hepatic concentrations of tetrahydrobiopterin (BH4, an es-
sential cofactor for PAH) (Chen et al., 2007), or differences
in intestinal absorption and transport of Phe (Scriver and
Waters, 1999), may also contribute to the lower Phe tolerance
observed in treated PKU female mice. In this regard, experi-
ments with nonviral vectors designed for stable liver-directed
genomic integration of a PAH expression cassette (Chen and
Woo, 2007) or with AAV vectors pseudotyped with serotype 8
capsid (rAAV2=8) (Ding et al., 2006b; Harding et al., 2006b)
also indicated that a higher therapeutic threshold is required
for long-term correction of PKU in females. Recombinant
AAV2=8 has been reported to be 10 to 100 times more effec-
tive in liver than rAAV2=2 and rAAV2=5, respectively (Sarkar
et al., 2004). In addition to the role of the AAV capsid in gene
transfer, the number of hepatocytes that are successfully
transduced, even when high doses of AAV vector are used, is
highly influenced by the routes of administration for AAV
delivery (Berraondo et al., 2006; Inagaki et al., 2006). Indeed,
our previous study showed a more robust and longer lasting
correction of hyperphenylalaninemia in both male and female
PKU mice when rAAV2=8 vectors were delivered via the
portal vein rather than by the tail vein (Ding et al., 2006a).
In that experiment, expression of the PAH gene was driven
by the constitutive or ubiquitous cytomegalovirus (CMV)
enhancer–chicken b-actin (CBA) promoter. Although thera-
peutic corrections up to 53 weeks (for more than 1 year) have
been observed for some animals, we also noticed a loss of
effectiveness starting at about week 40 in female mice. To-
gether, these observations emphasize the need to further ex-
tend the therapeutic persistence achieved with rAAV2=8
vectors and to find alternative AAV serotype vectors if re-
peated gene vector delivery is required.
In this study, we performed a dose–response and time
course analysis of the efficiency of recombinant AAV2=1,
AAV2=2, and AAV2=8 vectors, expressing the murine Pah
gene from the CBA promoter, and delivered by direct in-
tramuscular injection rather than intravenously, to mediate
liver transduction and correct hyperphenylalaninemia in
Pahenu2 mice, a model of human PKU. The superiority of
rAAV2=1 and rAAV2=8 vectors over rAAV2=2 vector in
achieving long-term therapeutic correction was reaffirmed.
More importantly, a therapeutic effect was observed in both
male and female treated mice, albeit more effective in males.
For treated female mice in which blood Phe levels had risen
again several weeks after gene transfer, supplementation
with BH4 cofactor led to transient restoration of blood Phe to
near normal levels. Alternatively, intramuscular injection of
rAAV2=8 vector extended therapeutic correction in females
previously exposed to rAAV2=1 vector.
Materials and Methods
Plasmid vectors and recombinant AAV production
The cloning strategy for the construction of plasmid
pAAV2-PKU5 has been previously described (Ding et al.,
2006a). Briefly, the transgene expression cassette flanked
by two inverted terminal repeats in pAAV2-PKU5 was
designed with the CMV enhancer–chicken b-actin (CBA)
promoter, the mouse 1.4-kb Pah cDNA, the woodchuck
posttranscriptional regulatory element (WPRE), and the
simian virus 40 (SV40) polyadenylation signal sequence.
Recombinant AAV2 vectors pseudotyped with serotype 1
or 8 capsid proteins were produced in an adenovirus-free
system in HEK 293 cells, using a three-plasmid transfection
protocol with the pAAV2-PKU5 plasmid, the adenovirus
helper plasmid pBS-E2A-VA-E4 (provided by H. Bu¨eler
[Paterna et al., 2004]), and a pAAV packaging plasmid
expressing the rep and cap genes. For pseudotyping with
serotype 1 and 8 capsid proteins, plasmids p5E18RXCI
and p5E18-VD2=8 were used, respectively (provided by
J.M. Wilson [Gao et al., 2002]). For the production of re-
combinant AAV2 serotype 2 vectors, a two-plasmid trans-
fection protocol was used with plasmids pAAV2-PKU5
and pDG, the latter carrying the AAV2 rep and cap genes,
as well as adenovirus helper genes (provided by J.A.
Kleinschmidt [Grimm et al., 1998]). All vectors were puri-
fied by two rounds of cesium chloride gradient centrifu-
gation to provide a uniform purification method. After the
second centrifugation, the peak fractions, as determined by
semiquantitative polymerase chain reaction (PCR), were
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dialyzed for three rounds against sterile phosphate-
buffered saline (PBS), and concentrated with Amicon Ultra
filters (Millipore, Billerica, MA) (Grieger et al., 2006). The
physical particle titers were determined by TaqMan anal-
ysis of the WPRE sequence with the following primers and
probe (Potter et al., 2002; Grieger et al., 2006): forward
primer, 50-CCGTTGTCAGGCAACGTG-30; reverse primer,
50-AGCTGACAGGTGGTGGCAAT-30; probe, 50-FAM-
TGCTGACGCAACCCCCACTGGT-TAMRA-30. A standard
curve was generated by dilution of vector plasmids in sal-
mon sperm DNA (40ng=ml) to increase the stability of
plasmid dilutions.
Animal experiments
Animal experiments were carried out in accordance with
the State Veterinary Office of Zu¨rich (Zu¨rich, Switzerland)
and Swiss law on animal protection, the Swiss Federal Act
on Animal Protection (1978), and the Swiss Animal Protec-
tion Ordinance (1981). All animal studies were approved by
the Cantonal Veterinary Office (Zu¨rich, Switzerland) and the
Cantonal Committee for Animal Experiments (Zu¨rich,
Switzerland). PAH-deficient C57BL=6-Pahenu2 (‘‘PKU’’) mice
were homozygous for the same Pah mutation as described
for the original BTBR-Pahenu2 strain (McDonald and Charl-
ton, 1997; Ding et al., 2006a). All mice were maintained on
standard mouse chow, and 8- to 10-week-old male and
female PKU mice were selected for viral injection. Fifty mi-
croliters of recombinant AAV vector suspension was injected
intramuscularly through the skin into both gastrocnemius
muscles in less than 1min (about 0.025ml=min); mice were
not included in this study if blood was present in the syringe
on withdrawal, or if the injected mice showed signs of
bleeding. Monitoring of blood Phe collected from tail veins
was carried out as described earlier (Ding et al., 2008). For
cofactor administration, BH4 from Schircks Laboratories
( Jona, Switzerland) was dissolved in 1% ascorbic acid, pH 7,
to a concentration of 10–100mM and administered to mice
(between 16 and 32mg of BH4 per kilogram body weight) by
intraperitoneal injection, using a 27-gauge needle on a 1-ml
disposable syringe. Note that when the first cohort of ani-
mals was injected with a dose of 32mg of BH4 per kilogram
body weight, we noticed moderate signs of weakness, pas-
sivity, and sluggishness in these animals; however, mice re-
ceiving 16mg of BH4 per kilogram body weight remained
asymptomatic after BH4 treatment. The amount of BH4 given
here is comparable to human doses for oral loading tests,
which are between 20 to 40mg of BH4 per kilogram body
weight. Tissue BH4 content was determined 24 hr after in-
traperitoneal injection as described (Ding et al., 2006a, 2008).
PAH enzyme assay and immunoblotting analysis
PAH enzyme activity in liver and muscle homogenates
was measured according to a published method (Tho¨ny et al.,
2004) with minor modifications of the homogenization pro-
cedure. Briefly, frozen harvested tissues were ground to
powder in liquid nitrogen, suspended in 1 vol (muscle) or 5
vol (liver) of cold lysis buffer, and homogenized with a
DUALL Kontes glass homogenizer (Kimble Chase, Vineland,
NJ). For immunoblot analysis, equal amounts of liver (20mg)
or muscle (30 mg) homogenate from wild-type or rAAV-
treated Pahenu2 mice were separated by 4–12% polyacryl-
amide gel electrophoresis (PAGE), blotted onto nitrocellu-
lose membrane, and probed with rabbit anti-PAH antibody
(diluted 1:10,000) or mouse anti-b-actin antibody (1:1000
or 1:10,000; Sigma-Aldrich, St. Louis, MO). The blots were
incubated with a secondary antibody conjugated with per-
oxidase (1:10,000; GE Healthcare Biosciences, Piscataway,
NJ) and the bands were visualized with enhanced chemi-
luminescence (ECL) solution (GE Healthcare Biosciences).
Quantification of Western blots was done with NIH Image
software, with the amounts of PAH protein normalized to
the amount of b-actin protein detected.
AAV vector biodistribution
Real-time PCR analysis of genomic DNA extracted from
snap-frozen tissues was performed with the same set of
primers and probe indicated in the preceding section, Plas-
mid Vectors and Recombinant AAV Production. Details of
the procedure have been described previously (Ding et al.,
2006a).
Statistical analysis
Statistical analyses were performed with GraphPad Prism
software (GraphPad Software, San Diego, CA). Statistical
differences between the various experimental groups were
evaluated by t test. p< 0.05 was considered statistically sig-
nificant.
Results
Dose response and kinetics of AAV serotype 1, 2,
and 8 vector-mediated correction of murine PKU
To compare the efficacy of various AAV serotypes for
mediating long-term therapeutic correction of PKU in Pahenu2
mice, we generated three different recombinant AAV2 ge-
nomes packaged with either serotype 1, 2, or 8 capsid. Each
of these vectors contained an identical expression cassette
consisting of the murine Pah cDNA under the control of the
CMV enhancer–chicken b-actin (CBA) promoter with a
woodchuck posttranscriptional regulatory element (WPRE)
sequence. This expression cassette, named AAV2-PKU5, was
previously described in our study of liver-directed gene
transfer via intraportal or tail vein injection of recombinant
AAV vectors (Ding et al., 2006a). The AAV particles pseu-
dotyped with serotype 1, 2, or 8 capsid (the vectors are
named AAV2=1-PKU5, AAV2=2-PKU5, and AAV2=8-PKU5,
respectively) were produced in the same manner to avoid
inconsistencies due to differences in purification methodol-
ogies (Klein et al., 2008). To evaluate the influence of the
various AAV capsid proteins on long-term therapeutic cor-
rection, hyperphenylalaninemic male and female Pahenu2
mice were first injected with an equivalent, high dose of viral
genomes (VG) of AAV2=1-PKU5 or AAV2=8-PKU5 vector
(1.21012 VG=mouse) or with a slightly higher dose of
2.41012 VG=mouse for the comparative study with
AAV2=2-PKU5. For each mouse, half of the total vector dose
was administered to each hindleg by direct percutaneous
injection into the gastrocnemius muscles. Given the low in-
vasiveness of intramuscular injections, this route would be
more advantageous for secondary gene transfer than in-
traportal delivery, and thus was selected for this study.
Blood Phe levels were monitored periodically for several
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weeks and used as a surrogate marker of transgene expres-
sion. In all treatment groups, blood Phe levels decreased
significantly from levels greater than 1800 mM to less than
360 mM, the defined therapeutic value for blood Phe, by
2 weeks after vector injection, and this effect persisted in all
injected mice, both males and females, for at least 10 weeks
(Fig. 1). Normalization of Phe levels was also accompanied
by a complete phenotypic change from brown hair to black
at about 8 weeks, similar to results we (and others) have
observed in previous studies (Ding et al., 2006a, 2008). The
duration of correction in males was monitored for more than
1 year and the results are summarized as follows: In males
injected with the highest dose of vector AAV2=1-PKU5,
AAV2=2-PKU5, or AAV2=8-PKU5, blood Phe levels were
stably maintained at low levels for 54, 40, and 55 weeks
postinjection, respectively. Blood Phe values rose slightly
above 360mmol=liter in some mice injected with AAV2=
8-PKU5 at week 55, the last time point analyzed (Fig. 1c).
Similarly, side-by-side comparative analyses were performed
in females and the results showed striking differences in
treatment effect between males and females, and among the
three vectors tested. Although the normalization of blood
Phe levels in females treated with the highest doses of
AAV2=1-PKU5 and AAV2=8-PKU5 were temporary, they
lasted out to 30 and 35 weeks postinjection, respectively
(see Fig. 1a and c). Interestingly, blood Phe levels did not
return to pretreatment values (:1800 mmol=liter), and all
females remained only mildly hyperphenylalaninemic with
Phe concentrations ranging from 700 to 900 mmol=liter up to
1 year. In female mice, AAV2=2-PKU5 treatment was least
effective (Fig. 1b), as the Phe values in this cohort of mouse
began to rise 10 weeks after gene transfer and returned to
levels close to pretreatment values by 30 weeks.
Because these comparisons were made with relatively
high vector doses, we wanted also to exclude the possibility
that a potential vector hierarchy had been obscured because
of saturating conditions. Therefore, we proceeded to test the
long-term correction efficiency of the various AAV vectors in
a dose range study. At a dose of 1.21011 VG=mouse, sta-
tistically significant correction in blood Phe was seen only in
animals treated with AAV2=8-PKU5 vector (Fig. 1c) and not
in mice receiving either AAV2=2-PKU5 or AAV2=1-PKU5.
The therapeutic effect with AAV2=8-PKU5 vector, however,
was only transient; blood Phe rose again to preinjection
levels by 10 weeks postinjection. Only modest decreases in
blood Phe were observed after treatment with 1.21011 VG
of AAV2=1-PKU5 (Fig. 1a), 2.41011 VG of AAV2=2-PKU5
(Fig. 1b), or with a lower dose (1.21010 VG=mouse) of
AAV2=8-PKU5 (Fig. 1c). In all cases, this modest effect lasted
only a few weeks. As was expected, the results from the
dose–response study confirmed that rAAV vector pseudo-
typed with serotype 8 capsid was the best performing vector.
Surprisingly, however, at the highest dose, AAV serotypes 1
and 8 were almost equally effective in yielding long-term
correction of blood Phe levels in both male and female
Pahenu2 mice.
Tissue distribution of rAAV vector DNA
We anticipated that murine liver would be the principal
target for transduction and PAH expression in our experi-
ments because of the established general hierarchy of tissue-
FIG. 1. Serotype-, dose-, and gender-dependent changes of
blood phenylalanine (Phe) content in phenylketonuria (PKU)
mice after intramuscular administration of vector AAV2-
PKU5. Various doses of vector AAV2-PKU5 expressing
phenylalanine hydroxylase (PAH) and pseudotyped with
either capsid 1, 2, or 8 were injected into the gastrocnemius
muscles of both hindlegs of male and female PKU mice.
Approximately every second week blood was withdrawn
from tail veins for Phe determination, depicted as a func-
tion of time after injection of AAV2-PKU5. Blood Phe con-
centrations are represented as means SD. The dotted lines
in each graph indicate the therapeutic threshold of blood
Phe concentration for treatment of patients with PKU
(9360 mmol=liter). (a) Vector AAV2-PKU5 serotype 1 was
injected at a dose of 1.21012 viral genome (VG) particles per
mouse in males (red circles, n¼ 4) and in females (blue
squares, n¼ 3), or at a dose of 1.21011 VG particles per
mouse (black triangles, 3 males plus 3 females, n¼ 6). (b)
Vector AAV2-PKU5 serotype 2 was injected at a dose of
2.41012 VG particles per mouse in males (red circles, n¼ 2),
and in females (blue squares, n¼ 2), or at a dose of 2.41011
VG particles for the lower dose–response study (black tri-
angles, male, n¼ 3). (c) Vector AAV2=8-PKU5 serotype 8 was
injected at three different vector doses, in 10-fold increments,
ranging from 1.21010 to 1.21012 VG particles per mouse.
Data for males (red circles, n¼ 4) and females (blue squares,
n¼ 3) are plotted separately for the 1.21012 VG particle
dose–response study, whereas vector doses of 1.21010 VG
particles (black inverted triangles, n¼ 3) and 1.21011 VG
particles (black triangles, n¼ 3) were used for injection of
two male groups. Blood Phe levels at various time points
after AAV2-PKU5 injection were compared with preinjection
blood levels by Student t test. Significant differences as
compared with t¼ 0 found for all AAV2-PKU5-treated ani-
mals are marked with asterisks, whereas at all unmarked
points blood Phe was not significantly different from base-
line levels ( p> 0.05).
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specific transduction efficiency of the various AAV serotypes
(Wu et al., 2006) and because the CBA promoter directs robust
gene expression in the liver. Furthermore, our previous studies
and those of others have demonstrated that tail vein adminis-
tration of recombinant AAV vector particles leads to prefer-
ential transduction of the liver (Davidoff et al., 2005; Ding et al.,
2006a). To confirm that hindlimb muscle injection of our vec-
tors led to vector accumulation in the liver in addition to
muscle deposition, and to further examine the influence of
factors such as dose, gender, and serotype on vector biodis-
tribution, AAV2-PKU5 vector genomes were quantified by
qPCR analysis from identical amounts of genomic DNA ex-
tracted from liver, hindleg and foreleg muscles, diaphragm,
heart, kidney, spleen, brain, and lung (see Table 1). In animals
that had received the highest vector dose (> 1.21012 VG),
AAV2-PKU5 vector DNAwas detected in all tissues examined,
but vector genome copies per cell (VG per cell) varied signifi-
cantly between the samples. For all threeAAV serotypes and in
both male and female mice, most vector genomes were de-
tected either in hindleg muscle tissue (the site of injection) or in
liver. Muscle tissue from hindlegs of AAV2 serotype 1-injected
mice contained the highest vector genome copy numbers per
cell followed by the serotype 8- and 2-treated groups, as ex-
pected from several reports of preferential transduction of
muscle tissue by rAAV2=1 vectors (Xiao et al., 1999; Chao et al.,
2000; Arruda et al., 2004; Louboutin et al., 2005). Betweenweeks
28 and 56 postinjection of rAAV2=8 vector, the number of
AAV2-PKU5 genomes measured in liver decreased roughly 8-
fold whereas the number of genomes measured in the injected
muscle decreased only by half. This difference may reflect the
hepatocyte turnover rate and accelerated episomal vector
clearance in liver in comparison with muscle. Administration
of the highest dose (> 1.21012) of AAV vectors to female mice
also led to efficient liver transduction, which was, however, 2-
to 7-fold lower than the values found in the male cohort. The
gender difference in vector genome copy numbers in liver was
found to be highly significant for the AAV2 serotype 8-treated
group ( p¼ 0.0013 by Student t test). Such sex-dependent dif-
ferences in transduction of murine liver by AAV has also been
reported by other groups (Davidoff et al., 2003) (see also Dis-
cussion). A gender difference formuscle (hindleg) transduction
with vectors serotype 1 and 8 was also observed, but this dif-
ference was much less pronounced than for liver. The gender
difference in vector genome copy numbers per cell for all three
AAV serotypes is also reflected in the difference for long-term
Phe clearance as shown in Fig. 1. In contrast to liver, the dif-
ference in hindlegmuscle transduction for bothAAV2 serotype
1 and 8 vectors seemed to be slightly less pronounced between
females and males, with values in females decreasing by only
approximately one-third to one-fourth compared with copy
number in males. Similar gender-related differences were no-
ted at lower vector doses (Table 1). The biodistribution of these
vectors in all other tissues, that is, foreleg muscle, diaphragm,
heart, kidney, spleen, brain, and lung, was also influenced by
the AAV capsid proteins. The overall results suggested a gen-
der-related difference in vector distribution especially observ-
able for the serotype 8 vector.
Tissue PAH activities
In general, the transduction profile found in liver or
muscle was also reflected in the tissue PAH activity (Table 2).
Most notably, the results indicated that liver PAH activities
ranging from 0.25 to 0.58mU=mg, equivalent to 10–23% of
wild-type liver PAH activity, were sufficient to maintain
blood Phe levels well below the curative threshold. Fur-
thermore, for some mice, values of 0.10mU=mg, equivalent
to 4% wild-type liver PAH activity, were associated with Phe
concentrations between 742 and 839 mmol=liter, which are
considered to be characteristic levels of mild human hyper-
phenylalaninemia. Unfortunately, the relationship between
wild-type protein levels and liver PAH activity could not be
assessed through immunoblotting because of indiscriminate
detection of both wild-type and mutant PAH proteins in
livers of Pahenu2 mice (Ding et al., 2004) and insufficient
amounts of vector-mediated PAH expression to enable rel-
ative quantitation of expression levels between treated and
untreated Pahenu2 mice (data not shown). In contrast, the
results from Western blot analysis of vector-injected muscles
demonstrated a direct correlation between vector genome
copy number and amount of detectable PAH protein (data
not shown).
Administration of rAAV2=8 after prior injection
with rAAV2=1 vector
Several studies have reported strategies to increase or
sustain transgene expression levels through serial injection of
rAAV vectors with alternative capsid serotypes to avoid
immunity against previously administered viral vectors
(Halbert et al., 2000; Riviere et al., 2006; Nathwani et al., 2009).
Because rAAV-treated Pahenu2 females were more reluctant
to achieve long-term therapeutic correction than males, we
sought to examine whether it might be possible to further
extend the therapeutic duration by administering an alter-
native serotype vector. For this purpose, two Pahenu2 females,
which had been previously exposed to 1.21012 AAV2=1-
PKU5 vector genomes and with blood Phe values rising to
pretreatment levels by week 44 (Fig. 1a), were reinjected
intramuscularly with an equivalent dose of serotype 8 vector
(1.21012 VG of AAV2=8-PKU5 per mouse; see Fig. 2). Blood
Phe concentrations subsequently decreased from 1260
631 mmol=liter to therapeutic levels (<360mmol=liter) by
3 weeks after secondary injection. Blood Phe remained at
therapeutic levels up to 13 weeks after the second injection
but increased thereafter to reach values of mild hyperphe-
nylalaninemia (713.2 216 mmol=liter). It should be noted,
however, that in comparison with females only injected once
with vector AAV2=8-PKU5 and in which therapeutic Phe
levels were maintained up to 35 weeks (Fig. 1c), the thera-
peutic effect of AAV2=8-PKU5 treatment was less persistent
in animals receiving secondary injections. This observation
suggests that the transduction efficiency of secondary gene
transfer is likely to be influenced or affected by the delivery
of the first vector or by the age at which the animals were
treated the second time. Nonetheless, these results demon-
strate a successful method to prolong therapeutic correction
in female mice to a similar duration as was achieved in male
mice.
Effect of BH4 supplementation on blood phenylalanine
in rAAV-treated female mice
We have previously reported that the BH4 cofactor stim-
ulates and protects the activity of normal murine PAH in
468 REBUFFAT ET AL.
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liver (Tho¨ny et al., 2004; Scavelli, 2006; Pey et al., 2008).
Moreover, expression of PAH in skeletal muscle in the
presence of adequate BH4, or coexpression of PAH along
with the essential BH4 biosynthetic genes, can effectively
clear Phe from the circulation of PKU mice (Ding et al., 2008).
We reasoned that as liver PAH activity was lost in rAAV-
treated female mice, Phe clearance could be additionally
limited by relative BH4 cofactor deficiency. To test this hy-
pothesis, we supplemented BH4, using a single dose of
synthetic cofactor, by intraperitoneal injection of 16mg of
BH4 per kilogram body weight, an amount that is compa-
rable to the recommended oral loading tests in human pa-
tients, that is, 20mg of BH4 per kilogram of body weight.
Supplementation of BH4 was done for both male and female
mice 38 weeks after administration of rAAV2=2-PKU5 vector
(2.41011 VG=male mouse and 2.41012 VG=female mouse).
Blood Phe was measured before and 6, 12, and 24 hr after
BH4 injection. As shown in Fig. 3a, blood Phe in rAAV-
treated males was not affected by BH4 supplementation.
However, in female rAAV2=2-PKU5-treated mice, blood Phe
concentrations decreased transiently in response to BH4 in-
jection. Successful Phe clearance after BH4 treatment was
also observed for mice previously injected with the highest
rAAV2=8-PKU5 dose (Fig. 3b). To further assess whether
skeletal muscle tissue, which lacks endogenous cofactor
production, could participate in Phe clearance, BH4 respon-
siveness was compared between male mice injected with a
low dose of rAAV2=1-PKU5 (1.21011 VG=mouse; at week
53) and rAAV2=8-PKU5-treated females from the high-dose
cohort group (1.21012 VG=mouse; at week 56; see Table 1).
Retrospectively, the number of vector genomes measured in
DNA recovered from hindleg muscle was similar in these
two groups (75 17VG=cell in males compared with
79 7VG=cell in females), but the number of vector genomes
in liver was at least 6-fold lower in the rAAV2=1-PKU5-
treated group than in the rAAV2=8-PKU5-treated mice
(18 0.1VG=cell for rAAV2=1-PKU5 vs. 109 6VG=cell for
rAAV2=8-PKU5). In contrast to the rAAV2=8-PKU5-treated
mice, loading with BH4 either by a single intraperitoneal
injection or by repeated oral administration for 5 days (32mg
of BH4 per kilogram body weight per day) did not result in a
decrease in blood Phe levels in rAAV2=1-PKU5 mice (data
not shown). These results indirectly show that in our setting
only liver, not muscle, PAH activity profits from BH4
cofactor treatment.
We subsequently addressed further the possibility that
BH4 content in the livers of treated animals could be a lim-
iting factor for Phe clearance; we therefore investigated di-
rectly the effect of exogenously administered cofactor on
residual PAH activity. As shown in Fig. 4a, no significant
difference in liver BH4 levels before BH4 supplementation
was found between successfully corrected rAAV-injected
males, partially corrected rAAV-injected females, or wild-
type females ( p> 0.05 by one-way analysis of variance
[ANOVA] followed by Bonferroni’s post hoc test). To con-
firm that BH4 was effectively taken up into liver and muscle
after intraperitoneal injection, we measured BH4 content in
tissues of rAAV-treated animals (Fig. 4b). Twenty-four hours
after BH4 administration by intraperitoneal injection, BH4
content had increased more than 5-fold in liver over pre-
treatment levels in females injected with rAAV2=8-PKU5
vectors (Fig. 4a and b) and was almost 4-fold higher in
muscle of BH4-treated mice in comparison with wild-type
mice that had not received BH4 (Fig. 4b). Similar results were
seen in male mice that had been treated with rAAV2=8-PKU5
(Fig. 4b). BH4 supplementation in both female and male
rAAV-treated mice was associated with a 3.3- and 2.3-fold
increase, respectively, in measured liver PAH activity com-
pared with untreated Pahenu2 animals. The increased PAH
activity was apparently sufficient to allow therapeutic Phe
clearance in these mice (see Figs. 3b and 4c). A 1.7-fold in-
crease in PAH activity on BH4 treatment was also found in
hindleg muscle from both genders (Fig. 4d). To further assess
the direct effect of BH4 supplementation on PAH, immuno-
blotting and densitometric quantification of PAH protein
were performed. In liver of rAAV2=8-PKU5 treated mice, we
observed an*2-fold increase in PAH protein levels after BH4
loading (Fig. 4e). In contrast to rAAV-transduced liver,
where BH4 might have stabilized both endogenous mutant
PAH monomers and wild-type PAH protein expressed from
the vector transgene, muscle homogenate containing only
transgenic wild-type PAH protein was used to assess the
direct relationship between PAH protein levels with and
FIG. 2. Time course of blood Phe levels in PKU female mice
after readministrations of AAV2-PKU5 vectors pseudotyped
with alternative serotypes 1 and 8. (a) Time diagram for the
intramuscular readministration experiment using alternative
serotypes. At time point 44 weeks, 1.21012 particles of
vector AAV2=1-PKU5 (serotype 1) was injected into both
hindleg muscles of PKU females (n¼ 3). Forty-four weeks
later, indicated as time 0 in the graph, two females were
subjected to a second injection with 1.21012 viral particles of
vector AAV2=8-PKU5 (serotype 8). (b) Blood Phe values of
PKU female mice after reinjection. At each time point the
result is represented as the mean SD. The dotted line in-
dicates the threshold for Phe concentration at the therapeutic
level (9360 mmol=liter).
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without BH4 supplementation. As shown in Fig. 4f, slightly
higher PAH protein levels were detected in both hindleg and
foreleg muscle homogenates on BH4 treatment compared
with untreated females, that is, a 1.3-fold increase by densi-
tometric analysis for the hindleg and a 20-fold increase for
foreleg muscles. In rAAV2=8-PKU5-treated males, which re-
ceived a 10-fold lower virus dose compared with the female
group, PAH protein levels were at or slightly below the
detection limit of our antibody, as we detected PAH protein
only in hindleg muscle of animals supplemented with BH4.
Taken together, these results suggest that the liver PAH
activity in treated Pahenu2 animals, which had not led to ef-
ficient removal of circulating Phe, could be increased by
exogenous BH4 supplementation. In contrast, heterologous
expression of PAH in muscle tissues with or without BH4
administration did not result in blood Phe clearance. Because
in the BH4-treated mice a 10- to 15-fold lower amount of BH4
was found in muscle tissues compared with liver, the rate of
BH4 uptake in muscle tissues could have been the limiting
factor in the clearance of circulating Phe. The slow rate of
BH4 uptake in muscle in comparison with liver has been
reported previously (Harding et al., 1998, 2004). Alter-
natively, the level of PAH protein expression in muscle of
rAAV-treated mice could have been insufficient for effective
blood Phe clearance even after supplementation with BH4.
Discussion
Recombinant AAV gene delivery vectors, owing to the
variety of applications and tissue types toward which these
vectors may be targeted, hold great promise for the treat-
ment of a multitude of genetic disorders and acquired
human disease (Alexander et al., 2008). Several studies have
shown that administration of rAAV vectors to a variety of
animal models including mice, dogs, and nonhuman pri-
mates can result in long-term gene expression and disease
correction with minimal toxicity (Kootstra and Verma, 2003).
These efforts have culminated in various clinical phase I–II
studies with AAV2 serotype 2 (Edelstein et al., 2007). Re-
gardless of the success with these approaches, gene therapy
correction in those models is currently limited to a period of
1 year or longer because of progressive decline in transgene
expression over time, indicating that vector readministration
may be necessary at intervals of several years. Furthermore,
FIG. 3. Effect of BH4 supple-
mentation in AAV2=2-PKU5-
and AAV2=8-PKU5-treated PKU
mice. PKU mice that underwent
AAV vector administration were
given a single intraperitoneal in-
jection of BH4 either when their
blood Phe levels started to rise
again and nearly reached pre-
treatment levels, or when they
had only a marginal decrease in
Phe levels but no therapeutic
correction. Mean Phe levels SD
before BH4 administration versus
6, 12, and 24 hr posttreatment are
plotted (dotted line represents
the Phe level of 9360mmol=liter).
(a) Mean blood values for Phe
values versus time in AAV2=2-
PKU5 (serotype 2)-treated PKU
males (circles, n¼ 3) and female
mice (squares, n¼ 2) after a sin-
gle intraperitoneal injection of
BH4. BH4 injections were per-
formed 38 weeks after gene
transfer in males and females
previously injected with 2.41011
and 2.41012 particles of vector
AAV2=2-PKU5 (serotype 2), re-
spectively. (b) Same as in (a), but
mice were pretreated with vector
AAV2=8-PKU5 (serotype 8):
squares, males (n¼ 3) 28 weeks
after gene transfer of 1.21010
VG; inverted triangles, males
(n¼ 3) 34 weeks after gene
transfer of 1.21011 VG; trian-
gles, females (n¼ 2) 56 weeks af-
ter gene transfer of 1.21012 VG.
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sex-related differences in biodistribution, differences in
transduction efficiency, the lack of identified cell receptors
for many rAAV serotypes, timing of expression, and levels of
transgene expression observed in many preclinical experi-
ments with AAV vectors are other unsolved issues that may
critically impact the outcome of a gene transfer approach
(Davidoff et al., 2003; Berraondo et al., 2006; Ogura et al.,
2006; Wu et al., 2006; Buning et al., 2008; Ho et al., 2008).
Thus, the development and investigation of multiple or
combined treatment strategies may offer alternative options
FIG. 4. Effect of BH4 supplementation on PAH in AAV2-PKU5-treated mice. BH4 content and PAH activity are indicated as
means SD. Note that all AAV2=8-PKU5-treated female PKU mice were at week 56 after gene transfer of 1.2  1012 VG
injected, and all AAV2=8-PKU5-treated male PKU mice were at week 34 after gene transfer of 1.21011 VG injected. (a) Total
hepatic BH4 content was analyzed in two groups of AAV2-PKU5-treated PKU male (n¼ 7) and female (n¼ 7) mice, and
compared with levels of normal wild-type females (WT; n¼ 5). For both groups of virus-treated PKU mice, the liver BH4
content of four AAV2=1-PKU5-treated animals and three AAV2=8-PKU5-treated animals was analyzed. (b) Total BH4 content
in liver and skeletal muscle of females (n¼ 2) and males (n¼ 2), both treated with rAAV2=8-PKU5 vectors, 24 hr after
intraperitoneal injection of synthetic cofactor (1 mmol=g body weight in 1% ascorbic acid). The black column indicates the BH4
content in muscle extracts of normal mice as control (not injected with synthetic BH4; n¼ 3). (c and d) PAH enzyme activities
in liver and muscle extracts, respectively, in the same animals as shown in (b), that is, 24 hr after BH4 treated (n¼ 2) compared
with non-BH4-treated (n¼ 1) AAV2=8-PKU5-injected mice. The black column in (c) indicates PAH activity of normal mouse
liver extracts (WT; n¼ 3). Note that muscle PAH activity between the sexes is different in (d), as males received a 10-fold
lower dose of AAV vectors than females. (e and f) Western blot analyses of liver and muscle extracts, respectively, from the
same BH4-treated and untreated mice. In (e) equal amounts of liver homogenate (20 mg) from a wild-type mouse (WT)
compared with AAV2=8-PKU5-treated PKU female mice with (þ) or without BH4 treatment () were probed with rabbit
anti-mPAH antibody (diluted 1:10,000). In (f) each lane contains 30 mg of homogenized hindleg (HL) or foreleg (FL) muscle
homogenate from animals treated with AAV2=8-PKU5 vectors after treatment with BH4 (þ) or no treatment (). Thirty
micrograms of liver homogenate of a wild-type mouse is shown as a control (WT). Bottom: Representative loading control
using an anti-b-actin antibody, diluted 1:10,000 in (e) and 1:1000 in (f).
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to further extend the therapeutic effect required and address
the issue of gender-dependent difference in transgene
expression.
We have reported two different approaches to achieve
long-term correction of hyperphenylalaninemia in a PKU
mouse model. In the first approach, liver-directed gene
transfer with the recombinant AAV2-PKU5 pseudotype 8
vector was explored, expressing the PAH transgene from the
CBA promoter (Ding et al., 2006a). Single doses of up to 1013
viral particle vectors administered by intraportal or tail vein
injection result in therapeutic correction lasting for up to 1
year for males and females. In a second approach, single
doses of approximately 1012 viral particles of a triple-cistronic
AAV pseudotype 1 vector encoding murine PAH along with
two BH4-biosynthetic enzymes expressed from a CMV pro-
moter were employed for muscle-directed gene transfer; this
approach was associated with therapeutic blood Phe clear-
ance for up to 70 weeks in our mouse model (Ding et al.,
2008). In both approaches, the therapeutic effect in some
mice persisted for 1 year or longer, whereas other animals, in
particular females, exhibited rising blood Phe levels at earlier
time points. Results from the biodistribution analysis in the
muscular approach study also indicated that some dissemi-
nation of vectors occurred to other tissues with preferential
accumulation in the liver, an observation that has been re-
ported by others (Manno et al., 2003; Asokan et al., 2008). On
the basis of this last observation and our previous studies,
we believe that long-term correction of hyperphenylalani-
nemia may further be strengthened by a concomitant mus-
cle- and liver-targeted gene transfer approach via
intramuscular injection. In the present study, we evaluated
the feasibility to effect long-term therapeutic correction of
PKU by intramuscular injection-mediated liver transduction
with various alternative rAAV serotypes as a preliminary
assessment toward multiple combined approaches. The
choice of AAV serotypes and the intramuscular administra-
tion route were selected for these experiments because (1)
liver as well as skeletal muscle have been successfully
transduced with rAAV pseudotype 8 in various animal
models (Sarkar et al., 2004; Wang et al., 2005; Inagaki et al.,
2006), and (2) rAAV2=8-mediated liver transduction is now
being considered for treatment of patients with hemophilia B
(Arruda et al., 2004). Similarly, rAAV pseudotype 1 is re-
portedly the most efficient vector for muscle transduction in
mice (Hauck and Xiao, 2003; Louboutin et al., 2005). rAAV
serotype 2 was also included in this study, being not only the
most well-characterized AAV serotype with modest tropism
for liver and muscle, but also having been used in clinical
phase I–II trials (Rabinowitz et al., 2002). To ensure that
differences between the vectors used here were limited to the
three different capsids, the rAAV2-PKU5 pseudotype 1, 2,
and 8 vectors were purified and concentrated in parallel by
an identical CsCl-density ultracentrifugation-based proce-
dure. We found that all three vector serotypes were able to
direct efficient clearance of serum Phe for at least 10 weeks
for males and females after intramuscular injection of doses
of 1.21012 for pseudotypes 1 and 8, or a dose of 2.41012 for
serotype 2. On the basis of vector biodistribution and PAH
activities determined in diverse tissues (see Tables 1 and 2),
significant amounts of viral vector genome were found only
in liver and hindleg muscles. The pseudotype 8 vector was
detected primarily in liver and pseudotype 1 in hindleg
muscle, and the relatively larger drop over time of vector
copy number in liver compared with hindleg muscle may
indicate a higher turnover rate in liver and more stable
maintenance of vector in muscle tissue (Table 1). Further-
more, loss of episomal viral genomes is thus a highly prob-
able explanation for the decrease in Phe clearance observed
over time in our experiments. Immunologic rejection of
transduced hepatocytes or myocytes has not been formally
ruled out, but we have never detected anti-PAH antibodies
in the blood of rAAV-treated mice and the histologic exam-
ination of transduced tissues was normal without any evi-
dence of lymphocyte infiltration (Ding et al., 2006a, 2008).
Interestingly, the results from the high dose–response ex-
periments showed that rAAV2-PKU5 with pseudotypes 1
and 8 were almost equivalent in mediating long-term Phe
clearance with persistently low blood Phe levels for up to 1
year in males, whereas females were corrected for at least 30
to 35 weeks after gene transfer.
The interaction between host and vector in the context of
gene therapy is complex and seems to vary considerably
according to vector type, serotype, dose, volume of injection,
and route of administration, as well as the species being
studied. This complexity also comes into play when trying to
interpret our finding. Evaluation of vector biodistribution in
this study did not provide direct evidence of rAAV vectors in
the blood, but results from preclinical and clinical reports
evaluating rAAV2=1 and rAAV2=8, as well as intramuscular
delivery protocols, suggest that leakage of vector from the
injection sites is likely to occur via the circulation. Kinetic
studies, for instance, have shown that the number of infec-
tious particles in the blood of mice or larger animals injected
with rAAV was maximal at 6 hr and accounted for 5% of
the total dose in one study and a 7-log less concentration of
the total injected dose in another study (Flotte et al., 2007;
Toromanoff et al., 2008). The appearance of vector DNA in
blood was followed by rapid clearance to low or undetect-
able levels within 7 to 14 days after the injection and similar
outcome has also been observed in two clinical trials (Brantly
et al., 2009; Mingozzi et al., 2009). These observations, along
with the extensive vascularization of skeletal muscle, would
favor AAV dissemination via the systemic circulation to
other organs such as the liver. However, the presence of viral
vector in draining and distant lymph nodes of animals in-
jected intramuscularly suggests that the lymphatic system
may participate in the dissemination of viral vector as well
(Rip et al., 2005).
Notwithstanding that the selection of an appropriate
capsid serotype is of pertinent importance to deliver AAV
vectors to specific target tissues, the intrinsic interactions
between various serotypes and muscle tissues could also
have affected the amount of vector that went into the blood
and then transduced the liver. It is likely that any serotypes
that would be efficiently internalized by muscle myofibers
could lead to less transduction of remote sites owing to the
low number of infectious particles gaining access to the
blood. This might explain why the injection of a low dose of
serotype 1, which is known to transduce muscle well, was
not as efficient as serotype 8 in transducing hepatocytes.
Data also suggest that rAAV2=1 can be viewed as a serotype
with low intramuscular diffusion abilities, leading to high
transgene expression at the intramuscular injection site ver-
sus low expression in the surrounding area (Toromanoff et al.,
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2008). Thus, with high-dose vector injection it might be
possible that local saturation of serotype 1 vector internali-
zation may have resulted in a higher concentration of viral
particles circulating in the blood and thus better liver
transduction. On the other hand, a differential rate of dis-
semination might also be explained by the relative amount of
cellular receptor and its affinity for a particular serotype.
Strong binding to heparan sulfate proteoglycans, which are
abundantly expressed on the surface of muscle cells, might
decrease the dissemination of AAV2=2 vector from the site of
administration (Asokan et al., 2008). In addition, it has also
been hypothesized that some specific serotypes, such as
AAV1, in certain tissues such as skeletal muscle may be
trapped as intact infectious particle in ‘‘protective’’ locations
such as the transverse tubules and could then be slowly re-
leased over time into the systemic compartment (Toromanoff
et al., 2008).
AAV vectors were also delivered intramuscularly with a
total injection volume of 50 ml administered to each hindlimb.
This injection volume in a 30-g mouse would be equivalent
to injecting 130ml into the muscle of an 80-kg human. Cer-
tainly, the injection volume and the resulting hydrostatic
pressure in the injected muscle body could influence the
amount of vector that gains access to the vasculature and is
transported to the liver. We have not investigated this vari-
able in detail. Reportedly, intramuscular injection of human
a1-antitrypsin (AAT)-expressing rAAV2=8 vector in a 0.4-ml
volume into mice yielded 9-fold higher serum hAAT levels
than in mice receiving the same vector dose but concentrated
in 0.01ml (Ye et al., 2009). In human clinical trials with in-
tramuscular administration of AAV vectors, total doses of
10–20ml divided into 0.3- to 0.5-ml injections were delivered
to multiple injection sites. Administration of 20ml to an
80-kg person would be equivalent to injecting only 8 ml into a
30-g mouse. Despite the relatively low injection volume
used, AAV vector administered to muscle has been detected
in the blood of human subjects treated in clinical trials
(Manno et al., 2003).
We witnessed a time-dependent loss of therapeutic effect
after rAAV injection in some animals, particularly in female
mice. BH4 supplementation by intraperitoneal injection tran-
siently improved Phe clearance but only in those mice that
had retained some minimal amount of liver PAH activity. The
molecular mechanisms that mediate BH4 responsiveness are
not yet completely elucidated, but several in vitro and in vivo
studies support the hypothesis that BH4 plays a role in the
protection of PAH protein against degradation (Tho¨ny et al.,
2004; Scavelli et al., 2005). The therapeutic effect of rAAV
treatment was much longer lasting in male mice than in fe-
male mice with all vector pseudotypes and doses. The reasons
for this difference have not been completely elucidated. Sec-
ond injection of rAAV vector with alternative capsid pseu-
dotypes into previously treated female mice did lead to
transient restoration of blood Phe to therapeutic levels.
However, the duration of this effect was shorter in animals
receiving secondary injections than in naive mice injected for
the first time. The cause for this discrepancy is yet unknown.
Possible explanations include an immunologic response aris-
ing after the first injection that then cross-reacts with the
second vector injected. Other investigators have also shown
that initial treatment with AAV serotype 2 vectors led to a 20-
fold impairment of subsequent rAAV pseudotype 1-mediated
transduction (Xiao et al., 1999). The extent of this impairment
seems dependent on the species treated, the route of vector
administration, and the specific vector pseudotype. We cannot
exclude the possibility that the age of the mice at the time of
the secondary injections may have influenced the effectiveness
of the treatment. Our experiment confirmed the previously
reported observation that transduction frequency after rAAV
administration is gender dependent, especially for rAAV2=8-
mediated liver transduction, but we did not detect a gender
difference in hepatic BH4 cofactor content, a subject of previ-
ous conjecture (Chen et al., 2007).
The animal model used here for PKU obviously has species
limitations related to assessing function, immune response,
and distribution of PAH. Because a primate model for the
disease is not available, at this point it is difficult to design
preclinical studies that accurately predict clinical outcomes.
Moreover, animals such as mice cannot provide data directly
applicable to human subjects, especially on safety and im-
munologic profiles. Another critical issue in translation to
human patients involves vector delivery across the vascular
barrier. Although this has been achieved in the PKUmouse by
using AAV in this and our previous works (Ding et al., 2006a,
2008), successfully translating rodent studies to patients re-
mains a challenge. Furthermore, dosing issues are also para-
mount in scaling gene delivery from small animal to human
patients. In the absence of a large animal model for PKU,
preclinical studies will surely necessitate the use of therapeutic
transgenic surrogate genes such as luciferase, green fluores-
cent protein (GFP), or a more relevant marker such as, for
example, a PAH-FLAG-tagged protein.
In summary, intramuscular injection of rAAV vectors, the
relatively noninvasive gene transfer strategy used in this
study, is as effective as our previous intravenous vector ad-
ministration (Ding et al., 2006) in producing therapeutically
relevant levels of liver PAH expression and successful cor-
rection of Phe clearance in an animal model of human PKU.
However, and in the light of the dose-dependent immune
toxicity and rAAV-related liver genotoxicity (Manno et al.,
2006; Zaiss and Muruve, 2008), it is perhaps critical to em-
phasize that in this study a 17-fold lower dose of rAAV2=
8-PKU5 vector was used than in our previous report on liver-
directed gene transfer via the portal vein and tail vein. BH4
supplementation or secondary injection of an rAAV vector
with an alternative capsid pseudotype can help sustain liver
PAH activity as PAH expression wanes over time. Perhaps
the future development of rAAV vectors that mediate site-
specific integration of the therapeutic transgene into the host
genome will lead to sustained liver PAH expression. Gene
therapy using the phenylalanine ammonia lyase (PAL) en-
zyme expressed from a viral or nonviral system might be an
alternative treatment approach. Results from preclinical and
clinical phase I studies using PAL as an enzyme substitution
therapy are encouraging and, further, PAL does not require
any exogenous cofactors (Sarkissian and Gamez, 2005; Sar-
kissian et al., 2008, 2009; Kang et al., 2010). All these studies
have the goal to develop a safe and efficient gene transfer
method for the long-term treatment of human PKU.
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